ALPHE — Pherecydes Pharma SA Share Price
Last trade - 00:00- €14.44m
- €15.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.79 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -58.5% | ||
| Return on Equity | -53.79% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | 9.1 | 41.1 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pherecydes Pharma SA is a France-based company. The Company is specialized in the research and development of anti-infective therapies based on bacteriophages. It deploys Phagotherapy, which is a method to treat bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells. The Company focuses on the selection, characterization, and production of therapeutic bacteriophages to combat antibiotic resistance through the selection of lytic phages. It produces therapeutic bacteriophages mainly to fight against the bacteria such as Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
Directors
- Guy-Charles Fanneau de la Horie CHM
- Pascal Birman OTH
- Celine Breda OTH
- Cindy Fevre OTH
- Philippe Rousseau OTH
- Frederique Vieville OTH
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- March 23rd, 2010
- Public Since
- July 22nd, 2015
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 7,221,477
- Address
- 22, boulevard Benoni Goullin, NANTES, 44200
- Web
- https://www.pherecydes-pharma.com/
- Phone
- +33 141506204
- Auditors
- PricewaterhouseCoopers Audit
Upcoming Events for ALPHE
Similar to ALPHE
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
As of Today at 01:17 UTC, shares in Pherecydes Pharma SA are trading at €2.00. This share price information is delayed by 15 minutes.
Shares in Pherecydes Pharma SA last closed at €2.00 and the price had moved by -54.02% over the past 365 days. In terms of relative price strength the Pherecydes Pharma SA share price has underperformed the FTSE Global All Cap Index by -58.61% over the past year.
The overall consensus recommendation for Pherecydes Pharma SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePherecydes Pharma SA does not currently pay a dividend.
Pherecydes Pharma SA does not currently pay a dividend.
Pherecydes Pharma SA does not currently pay a dividend.
To buy shares in Pherecydes Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €2.00, shares in Pherecydes Pharma SA had a market capitalisation of €14.44m.
Here are the trading details for Pherecydes Pharma SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALPHE
Based on an overall assessment of its quality, value and momentum Pherecydes Pharma SA is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pherecydes Pharma SA is €5.80. That is 190% above the last closing price of €2.00.
Analysts covering Pherecydes Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.40 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pherecydes Pharma SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -7.43%.
As of the last closing price of €2.00, shares in Pherecydes Pharma SA were trading -12.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pherecydes Pharma SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €2.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pherecydes Pharma SA's management team is headed by:
- Guy-Charles Fanneau de la Horie - CHM
- Pascal Birman - OTH
- Celine Breda - OTH
- Cindy Fevre - OTH
- Philippe Rousseau - OTH
- Frederique Vieville - OTH